Has Benjamin Medoff, MD received payments from drug or device companies?

Yes. Drug and device makers reported $97,768 in general payments to Benjamin Medoff, MD across 51 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Benjamin Medoff, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Benjamin Medoff, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Benjamin Medoff, MD

Critical Care Medicine · Boston, MANPI 1720062300

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $75,897 of the $97,768 with a category attached, or 77.6%. Sanofi accounts for 87.1% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $61,165 and has fallen 99.2% since, to $469 in 2025. Among critical care medicine clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$97,768in general payments, 2019–2025

Across 51 payments — averaging $1917.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$85K
Sanofi-aventis U.S. LLC$9K
AbbVie$3K
Partner Therapeutics, Inc.$450
Eli Lilly$315
Bristol Myers Squibb$131
plus $292 from 4 others

$1,170,774in research payments, 2019–2025

Across 53 payments — averaging $22,090 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Sanofi US Services Inc.$576K
Regeneron$460K
AstraZeneca$105K
Takeda Pharmaceuticals U.S.A., Inc.$30K

What the payments were for

Consulting fees$75,89778%
Travel & lodging$20,45621%
Food & beverage$1,4161%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	36	$85,187
Sanofi-aventis U.S. LLC	5	$8,643
AbbVie	2	$2,750
Partner Therapeutics, Inc.	1	$450
Eli Lilly	1	$315
Bristol Myers Squibb	1	$131
Regeneron Healthcare Solutions, Inc.	1	$107
Boehringer Ingelheim	1	$95
Lilly USA, LLC	2	$48
Sanofi US Services Inc.	1	$43

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$97,768 in reported general payments places this provider in the 95th percentile of 158 critical care medicine providers in Massachusetts.

See all critical care medicine providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$41,363

Medicare patients

168

Services billed

284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dupixent PenDupilumab	18	$65,843
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	25	$25,723
Incruse ElliptaUmeclidinium Bromide	27	$11,450
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr	13	$9,869
Wixela InhubFluticasone Propion/Salmeterol	31	$5,200
Fluticasone-SalmeterolFluticasone Propion/Salmeterol	14	$3,109
Albuterol Sulfate HfaAlbuterol Sulfate	31	$1,352
Omeprazole	20	$388
Azithromycin	12	$319
Prednisone	12	$36

Paid to pharmacies, not to this prescriber.

Other critical care medicine in Boston

Richard ChannickBoston$638K
Jerome CrowleyBoston$38K
Diana Espinoza BarreraBoston$17K
Catherine FioreBoston$13K
Ilana KrummBoston$13K
John ReichBoston$12K
Edward BittnerBoston$9K
Kenneth SheltonBoston$8K
Leo CeliBoston$8K
Michael ChoBoston$6K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →